Novel 5-azaindole factor VIIa inhibitors

We have developed a series of potent and selective factor VIIa inhibitors based on the 2-[5-(5-carbamimidoyl-1 H-benzoimidazol-2-yl)-6-hydroxy-biphenyl-3-yl]- succinic acid scaffold. These biaryl amidine-containing compounds suffer from low oral bioavailability. In an attempt to apply the knowledge...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 16; no. 12; pp. 3197 - 3200
Main Authors Riggs, Jennifer R., Hu, Huiyong, Kolesnikov, Aleksandr, Leahy, Ellen M., Wesson, Kieron E., Shrader, William D., Vijaykumar, Dange, Wahl, Troy A., Tong, Zhiwei, Sprengeler, Paul A., Green, Michael J., Yu, Christine, Katz, Brad A., Sanford, Ellen, Nguyen, Margaret, Cabuslay, Ronnel, Young, Wendy B.
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 15.06.2006
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We have developed a series of potent and selective factor VIIa inhibitors based on the 2-[5-(5-carbamimidoyl-1 H-benzoimidazol-2-yl)-6-hydroxy-biphenyl-3-yl]- succinic acid scaffold. These biaryl amidine-containing compounds suffer from low oral bioavailability. In an attempt to apply the knowledge we have gained from our amidine fVIIa inhibitor parenteral program to an oral program, we began with our 5-amidinobenzimidazole scaffold and replaced the amidine with a less basic 5-azaindole (1 H-pyrrolo[3,2- c]pyridine, 2). The discovery and development of 5-azaindole factor VIIa inhibitors will be described. The discovery and development of 5-azaindole factor VIIa inhibitors will be described.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2006.03.049